Aquestive Therapeutics Profit Margin

The latest profit margin for AQST is -144.63% as of June 2026. That compares with -147.38% in the prior-year period — up 1.9% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Aquestive Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AQST's profit margin moved from -147.38% to -144.63% — a 1.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aquestive Therapeutics's valuation or profitability profile.

Against Healthcare companies, AQST currently prints -144.63% for profit margin, while the sector average sits near 13.89%. That is roughly 1141.3% below the sector mean. Large gaps often invite a closer look at Aquestive Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Aquestive Therapeutics converts resources into returns. At -144.63%, AQST may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -147.38% in the prior-year period — up 1.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AQST's profit margin (-144.63%), review year-over-year change from -147.38%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.